JPMorgan Chase & Co. Has $8.67 Million Stock Holdings in Tyra Biosciences, Inc. (NASDAQ:TYRA)

JPMorgan Chase & Co. raised its holdings in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) by 1.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 368,647 shares of the company’s stock after purchasing an additional 3,896 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.73% of Tyra Biosciences worth $8,667,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in TYRA. HighVista Strategies LLC acquired a new stake in Tyra Biosciences during the 2nd quarter valued at $257,000. Franklin Resources Inc. acquired a new stake in Tyra Biosciences during the 3rd quarter valued at $278,000. Valence8 US LP acquired a new stake in Tyra Biosciences during the 3rd quarter valued at $310,000. SG Americas Securities LLC acquired a new stake in Tyra Biosciences during the 3rd quarter valued at $311,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in Tyra Biosciences during the 3rd quarter valued at $333,000. Institutional investors and hedge funds own 84.14% of the company’s stock.

Tyra Biosciences Stock Down 0.7 %

Tyra Biosciences stock opened at $15.10 on Tuesday. Tyra Biosciences, Inc. has a 12-month low of $12.17 and a 12-month high of $29.60. The business’s 50-day moving average price is $15.45 and its two-hundred day moving average price is $19.22. The stock has a market cap of $764.11 million, a PE ratio of -9.38 and a beta of 1.04.

Tyra Biosciences (NASDAQ:TYRA) last released its earnings results on Thursday, November 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.01). As a group, analysts expect that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of Tyra Biosciences in a report on Monday. UBS Group assumed coverage on Tyra Biosciences in a report on Tuesday, January 7th. They set a “buy” rating and a $28.00 target price for the company. Wedbush reissued an “outperform” rating and set a $28.00 target price on shares of Tyra Biosciences in a report on Friday, October 25th. Bank of America raised Tyra Biosciences from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $22.00 to $31.00 in a report on Friday, October 18th. Finally, Oppenheimer boosted their price target on Tyra Biosciences from $25.00 to $33.00 and gave the company an “outperform” rating in a research note on Thursday, September 19th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $30.50.

Insider Transactions at Tyra Biosciences

In other news, CEO Todd Harris sold 19,084 shares of the business’s stock in a transaction dated Monday, October 21st. The stock was sold at an average price of $27.90, for a total transaction of $532,443.60. Following the sale, the chief executive officer now directly owns 1,355,927 shares in the company, valued at approximately $37,830,363.30. The trade was a 1.39 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Alan Fuhrman purchased 9,500 shares of Tyra Biosciences stock in a transaction dated Wednesday, October 30th. The shares were purchased at an average price of $16.00 per share, for a total transaction of $152,000.00. Following the completion of the acquisition, the chief financial officer now owns 12,849 shares of the company’s stock, valued at approximately $205,584. The trade was a 283.67 % increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 74,125 shares of company stock worth $1,583,097. Insiders own 15.40% of the company’s stock.

Tyra Biosciences Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.